GIC-1001: Phase IIa started

gIcare began a double-blind, placebo-controlled, dose-ranging, U.S. and Canadian Phase IIa trial to evaluate thrice-daily 250, 375 and 500 mg oral GIC-100 for 3 days and a tenth dose given once 2 hour...